ABCB1 and colonic neoplasm: In the present in vitro study, we report that poziotinib can reverse MDR in colon cancer cells by antagonizing the efflux function of the ABCB1 and ABCG2 transporters, as well as decreasing the expression of the ABCG2 transporter protein.